From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
Naim Ata,1 Hasan Satış,2 Orhan Küçükşahin,3 Erdem Karabulut,4 Gizem Ayan,5 Abdulsamet Erden,6 Emre Bilgin,7 Berkan Armağan,8 Duygu Tecer,9 Hakan Babaoğlu,8 Alper Sarı,10 Levent Kıl&inodot...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-05-01
|
| Series: | Biologics: Targets & Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/from-conventional-to-advanced-therapies-a-national-health-registry-rep-peer-reviewed-fulltext-article-BTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157302991028224 |
|---|---|
| author | Ata N Satış H Küçükşahin O Karabulut E Ayan G Erden A Bilgin E Armağan B Tecer D Babaoğlu H Sarı A Kılıç L Ülgü MM Ayvalı MO Birinci Ş Kalyoncu U |
| author_facet | Ata N Satış H Küçükşahin O Karabulut E Ayan G Erden A Bilgin E Armağan B Tecer D Babaoğlu H Sarı A Kılıç L Ülgü MM Ayvalı MO Birinci Ş Kalyoncu U |
| author_sort | Ata N |
| collection | DOAJ |
| description | Naim Ata,1 Hasan Satış,2 Orhan Küçükşahin,3 Erdem Karabulut,4 Gizem Ayan,5 Abdulsamet Erden,6 Emre Bilgin,7 Berkan Armağan,8 Duygu Tecer,9 Hakan Babaoğlu,8 Alper Sarı,10 Levent Kılıç,5 Mustafa Mahir Ülgü,11 Mustafa Okan Ayvalı,11 Şuayip Birinci,12 Umut Kalyoncu5 1Department of Strategy Development, Republic of Turkey, Ministry of Health, Ankara, Turkey; 2Department of Rheumatology, University of Health Sciences Abdurrahman Yurtaslan Oncology Hospital, Ankara, Turkey; 3Department of Rheumatology, Ankara Yıldırım Beyazit University, Ankara City Hospital, Ankara, Turkey; 4Department of Biostatistics, Hacettepe University Faculty of Medicine Department, Ankara, Turkey; 5Department of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey; 6Department of Internal Medicine, Division of Rheumatology, Gazi University Medical Faculty, Ankara, Turkey; 7Department of Internal Medicine, Division of Rheumatology, Sakarya University Medical Faculty, Sakarya, Turkey; 8Department of Internal Medicine, Division of Rheumatology, University of Health Sciences Ankara City Hospital, Ankara, Turkey; 9Department of Internal Medicine, Division of Rheumatology, University of Health Sciences Gulhane Research and Training Hospital, Ankara, Turkey; 10Department of Internal Medicine Division of Rheumatology, University of Health Sciences Etlik City Hospital, Ankara, Turkey; 11General Directorate of Health Information Systems, Republic of Turkey, Ministry of Health, Ankara, Turkey; 12Republic of Turkey, Ministry of Health, Ankara, TurkeyCorrespondence: Hasan Satış, Department of Rheumatology, University of Health Sciences Abdurrahman Yurtaslan Oncology Hospital, Ankara, Turkey, Email hasansats@gmail.comObjective: There are national and international guidelines on the optimal use of disease-modifying anti-rheumatic drugs. In this study, we aimed to provide critical insights into the real-world efficacy and adherence of these DMARDs, providing a data-driven basis for optimizing treatment paradigms for RA within the national healthcare framework.Methods: This nationwide cohort study utilized data from the Turkish Ministry of Health National Electronic Database, known as E-Pulse between January 2016 and December 2022. In this analysis, cases of RA were identified using ICD-10 codes two times at least 30 days apart Treatment prescriptions were recorded based on their prescription at baseline and follow-up.Results: There were a total of 347,902 RA (79.5% female) patients in the E-Pulse system. The mean (SD) age of RA patients was 59.1 (14.8) years Methotrexate and sulfasalazine (35.1% vs 30.5%, OR 95% CI 0.81 usage was more common in men and hydroxychloroquine was more common in women 46.764 (13.4%) patients were prescribed bDMARD and/or tsDMARD 494.499 times. AntiTNF drugs are the most commonly prescribed drugs. This is followed by B-cell blockers, JAK inhibitors, anti-IL6 and T-cell blockers.Conclusion: Turkish national health database highlights the widespread use of synthetic DMARDs in treating rheumatoid arthritis (RA). While traditional DMARDs like methotrexate and hydroxychloroquine are favored the cautious use of advanced therapies, particularly anti-TNFs, suggests a potential for optimizing treatment protocols.Keywords: rheumatoid arthritis, treatment, nation-wide, disease modifying drug |
| format | Article |
| id | doaj-art-e8e89e9324ed4a2693347db0e238174a |
| institution | OA Journals |
| issn | 1177-5491 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Biologics: Targets & Therapy |
| spelling | doaj-art-e8e89e9324ed4a2693347db0e238174a2025-08-20T02:24:13ZengDove Medical PressBiologics: Targets & Therapy1177-54912025-05-01Volume 19Issue 1331339103298From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in TurkeyAta NSatış H0Küçükşahin O1Karabulut E2Ayan GErden A3Bilgin EArmağan B4Tecer D5Babaoğlu H6Sarı AKılıç L7Ülgü MM8Ayvalı MOBirinci ŞKalyoncu U9RheumatologyRheumatologyBiostatisticsDepartment of Internal Medicine, Division of RheumatologyRheumatologyRheumatologyRheumatologyInternal Medicine, Divisin of RheumatologyHealth Information SystemsHacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of RheumatologyNaim Ata,1 Hasan Satış,2 Orhan Küçükşahin,3 Erdem Karabulut,4 Gizem Ayan,5 Abdulsamet Erden,6 Emre Bilgin,7 Berkan Armağan,8 Duygu Tecer,9 Hakan Babaoğlu,8 Alper Sarı,10 Levent Kılıç,5 Mustafa Mahir Ülgü,11 Mustafa Okan Ayvalı,11 Şuayip Birinci,12 Umut Kalyoncu5 1Department of Strategy Development, Republic of Turkey, Ministry of Health, Ankara, Turkey; 2Department of Rheumatology, University of Health Sciences Abdurrahman Yurtaslan Oncology Hospital, Ankara, Turkey; 3Department of Rheumatology, Ankara Yıldırım Beyazit University, Ankara City Hospital, Ankara, Turkey; 4Department of Biostatistics, Hacettepe University Faculty of Medicine Department, Ankara, Turkey; 5Department of Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey; 6Department of Internal Medicine, Division of Rheumatology, Gazi University Medical Faculty, Ankara, Turkey; 7Department of Internal Medicine, Division of Rheumatology, Sakarya University Medical Faculty, Sakarya, Turkey; 8Department of Internal Medicine, Division of Rheumatology, University of Health Sciences Ankara City Hospital, Ankara, Turkey; 9Department of Internal Medicine, Division of Rheumatology, University of Health Sciences Gulhane Research and Training Hospital, Ankara, Turkey; 10Department of Internal Medicine Division of Rheumatology, University of Health Sciences Etlik City Hospital, Ankara, Turkey; 11General Directorate of Health Information Systems, Republic of Turkey, Ministry of Health, Ankara, Turkey; 12Republic of Turkey, Ministry of Health, Ankara, TurkeyCorrespondence: Hasan Satış, Department of Rheumatology, University of Health Sciences Abdurrahman Yurtaslan Oncology Hospital, Ankara, Turkey, Email hasansats@gmail.comObjective: There are national and international guidelines on the optimal use of disease-modifying anti-rheumatic drugs. In this study, we aimed to provide critical insights into the real-world efficacy and adherence of these DMARDs, providing a data-driven basis for optimizing treatment paradigms for RA within the national healthcare framework.Methods: This nationwide cohort study utilized data from the Turkish Ministry of Health National Electronic Database, known as E-Pulse between January 2016 and December 2022. In this analysis, cases of RA were identified using ICD-10 codes two times at least 30 days apart Treatment prescriptions were recorded based on their prescription at baseline and follow-up.Results: There were a total of 347,902 RA (79.5% female) patients in the E-Pulse system. The mean (SD) age of RA patients was 59.1 (14.8) years Methotrexate and sulfasalazine (35.1% vs 30.5%, OR 95% CI 0.81 usage was more common in men and hydroxychloroquine was more common in women 46.764 (13.4%) patients were prescribed bDMARD and/or tsDMARD 494.499 times. AntiTNF drugs are the most commonly prescribed drugs. This is followed by B-cell blockers, JAK inhibitors, anti-IL6 and T-cell blockers.Conclusion: Turkish national health database highlights the widespread use of synthetic DMARDs in treating rheumatoid arthritis (RA). While traditional DMARDs like methotrexate and hydroxychloroquine are favored the cautious use of advanced therapies, particularly anti-TNFs, suggests a potential for optimizing treatment protocols.Keywords: rheumatoid arthritis, treatment, nation-wide, disease modifying drughttps://www.dovepress.com/from-conventional-to-advanced-therapies-a-national-health-registry-rep-peer-reviewed-fulltext-article-BTTRheumatoid arthritistreatmentnation-widedisease modifiying drug |
| spellingShingle | Ata N Satış H Küçükşahin O Karabulut E Ayan G Erden A Bilgin E Armağan B Tecer D Babaoğlu H Sarı A Kılıç L Ülgü MM Ayvalı MO Birinci Ş Kalyoncu U From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey Biologics: Targets & Therapy Rheumatoid arthritis treatment nation-wide disease modifiying drug |
| title | From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey |
| title_full | From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey |
| title_fullStr | From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey |
| title_full_unstemmed | From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey |
| title_short | From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey |
| title_sort | from conventional to advanced therapies a national health registry report 2016 2022 on dmards in rheumatoid arthritis treatment in turkey |
| topic | Rheumatoid arthritis treatment nation-wide disease modifiying drug |
| url | https://www.dovepress.com/from-conventional-to-advanced-therapies-a-national-health-registry-rep-peer-reviewed-fulltext-article-BTT |
| work_keys_str_mv | AT atan fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT satısh fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT kucuksahino fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT karabulute fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT ayang fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT erdena fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT bilgine fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT armaganb fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT tecerd fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT babaogluh fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT sarıa fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT kılıcl fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT ulgumm fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT ayvalımo fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT birincis fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey AT kalyoncuu fromconventionaltoadvancedtherapiesanationalhealthregistryreport20162022ondmardsinrheumatoidarthritistreatmentinturkey |